Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 13
Submit an article Journal homepage
1,947
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Jennifer Woyacha Division of Hematology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3403-9144View further author information
ORCID Icon,
Alessandra Tedeschib Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, ItalyView further author information
,
Talha Munirc Department of Haematology, St. James's University Hospital, Leeds, UKView further author information
,
Tanya Siddiqid Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Peter Hillmene Department of Haematology, The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, UKView further author information
,
John C. Byrda Division of Hematology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USAView further author information
,
Paolo Ghiaf Division of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, ItalyView further author information
,
Stephen P. Mulligang Department of Haematology, Royal North Shore Hospital, University of Sydney, Sydney, AustraliaView further author information
,
Sandra Daih Department of Biostatistics, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USAView further author information
,
Carlos I. Amaya-Chanagai Department of Medical Affairs, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USAView further author information
,
James P. Deanj Department of Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USAView further author information
,
Susan M. O’Brienk Department of Hematology and Oncology, UC Irvine, Chao Family Comprehensive Cancer Center, Irvine, CA, USAView further author information
&
Paul M. Barrl Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USAView further author information
 show all
Pages 3278-3282 | Received 29 Mar 2021, Accepted 12 Jul 2021, Published online: 13 Aug 2021

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.